Figure 4.

(A) Overview plot depicting the complete clinical course of all patients within sub-cohort D, including the results of longitudinal ctDNA analysis. Patients with metastatic disease are marked with an asterisk “*” symbol. Blue diamond reflects initial/primary surgery performed to build the personalized ctDNA assay, all other additional surgeries are represented with grey diamonds. (A) Distribution of pathogenic and likely pathogenic driver mutations across all 7 patients in sub-cohort D. (C) Clinical course for patient #4 depicting initial surgery for high-grade LMS. A biopsy sample prior to surgery was used to design a personalized ctDNA assay. The patient received adjuvant RT post-surgery followed by a subsequent metastatic resection and immunotherapy.